sutent
pfizer limited - сунитиниб - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Антинеопластични средства - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
gefitinib zentiva 250 mg film - coated tablets
250 mg film - coated tablets
gefitinib sandoz 250 mg film-coated tablets
250 mg film-coated tablets
gefitinib teva 250 mg film - coated tablets
250 mg film - coated tablets
gefitinib pharmadvice 250 mg film - coated tablets
250 mg film - coated tablets
axitinib sandoz 1 mg film - coated tablets
1 mg film - coated tablets
axitinib sandoz 5 mg film - coated tablets
5 mg film - coated tablets
sunitinib alvogen 12,5 mg hard capsules
12,5 mg hard capsules
sunitinib alvogen 25 mg hard capsules
25 mg hard capsules
sunitinib alvogen 37,5 mg hard capsules
37,5 mg hard capsules